Literature DB >> 16291305

Use of imaging in the management of malignant pleural mesothelioma.

R E Benamore1, M J O'Doherty, J J Entwisle.   

Abstract

Malignant pleural mesothelioma (MPM) is an increasingly prevalent tumour. The death rate associated with MPM is predicted to peak in the next 10 years, although radiologists and clinicians will be encountering cases for the next few decades. Contrast-enhanced CT is an established technique for evaluating suspected malignant pleural disease, but MPM can be reliably diagnosed only by histological sampling. However, even with adequate sampling and the use of immunocytochemistry, histological diagnosis is known to be difficult; definitive diagnosis may involve a combination of clinical presentation, radiological and histological appearances. Percutaneous biopsy is a promising technique for sampling the pleura. In view of its pattern of growth, MPM is a challenging disease to image by any method, and it behaves quite differently from lung cancer. This review aims to highlight the practical aspects of assessing malignant pleural mesothelioma.

Entities:  

Mesh:

Year:  2005        PMID: 16291305     DOI: 10.1016/j.crad.2005.05.015

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  5 in total

Review 1.  Functional imaging: CT and MRI.

Authors:  Edwin J R van Beek; Eric A Hoffman
Journal:  Clin Chest Med       Date:  2008-03       Impact factor: 2.878

2.  Early and delayed phases of contrast-enhanced CT for evaluating patients with malignant pleural effusion. Results of pairwise comparison by multiple observers.

Authors:  Juan José Arenas-Jiménez; Elena García-Garrigós; Carmen Escudero-Fresneda; Marina Sirera-Matilla; Irene García-Pastor; Alberto Quirce-Vázquez; Mariana Planells-Alduvin
Journal:  Br J Radiol       Date:  2018-06-27       Impact factor: 3.039

3.  Multidetector CT imaging of pleura: comparison of two contrast infusion protocols.

Authors:  V Raj; R Kirke; M J Bankart; J J Entwisle
Journal:  Br J Radiol       Date:  2010-12-15       Impact factor: 3.039

4.  HER1-targeted 86Y-panitumumab possesses superior targeting characteristics than 86Y-cetuximab for PET imaging of human malignant mesothelioma tumors xenografts.

Authors:  Tapan K Nayak; Kayhan Garmestani; Diane E Milenic; Kwamena E Baidoo; Martin W Brechbiel
Journal:  PLoS One       Date:  2011-03-25       Impact factor: 3.240

5.  Early Contrast Enhancement: A novel magnetic resonance imaging biomarker of pleural malignancy.

Authors:  Selina Tsim; Catherine A Humphreys; Gordon W Cowell; David B Stobo; Colin Noble; Rosemary Woodward; Caroline A Kelly; Laura Alexander; John E Foster; Craig Dick; Kevin G Blyth
Journal:  Lung Cancer       Date:  2018-02-03       Impact factor: 5.705

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.